Research programme: cancer therapeutics - CorMedix/NanoProteagen

Drug Profile

Research programme: cancer therapeutics - CorMedix/NanoProteagen

Alternative Names: CRMD 005/vincristine; CRMD-005; Tauloridine/vincristine - CorMedix; Vincristine/tauloridine - CorMedix

Latest Information Update: 20 Sep 2016

Price : $50

At a glance

  • Originator CorMedix; National Cancer Institute (USA)
  • Developer CorMedix
  • Class Antineoplastics
  • Mechanism of Action Apoptosis modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Research Cancer

Most Recent Events

  • 20 Sep 2016 CorMedix and POETIC signs an agreement to develop therapies for rare orphan paediatric tumours
  • 20 Sep 2016 Early research in Cancer in USA (unspecified route)
  • 11 May 2016 CorMedix and NanoProteagen enter into two research licensing agreements for Neuroblastoma in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top